Table 2.
Clinical features and timeline of presentation of patients with Covid-19 vaccine associated lymphadenopathy
| Pt no. | Age (years) | Sex | 1st or 2nd dose | Injection site | Lymph node side | Symptom | Vaccination to lymphadenopathy* interval (days) | Lymphadenopathy to referral interval (days) | Referral to USS interval (days) | Outcome† | Time for outcome (weeks) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 54 | F | 1st | Left | Ipsilateral | Tenderness | 11 | 16 | 9 | Fully resolved | 8 |
| 2 | 27 | F | 1st | Left | Ipsilateral | Tenderness | 5 | 7 | 3 | Fully resolved | 3 |
| 3 | 60 | F | 1st | Left | Ipsilateral | None | 3 | 2 | 6 | Fully resolved | 2 |
| 4 | 40 | M | 1st | Left | Ipsilateral | None | 1 | 44 | 8 | Not documented | Not documented |
| 5 | 76 | F | 1st | Left | Ipsilateral | None | 4 | 17 | 7 | Partially reduced | 5 |
| 6 | 41 | F | 1st | Left | Ipsilateral | None | 7 | 26 | 10 | Fully resolved | 2 |
| 7 | 73 | F | 1st | Left | Ipsilateral | Tenderness | 7 | 7 | 5 | Fully resolved | 3 |
| 8 | 55 | F | 1st | Left | Ipsilateral | None | 14 | 41 | 12 | Partially reduced | 12 |
| 9 | 57 | F | 1st | Left | Ipsilateral | None | 2 | 37 | 12 | Partially reduced | 11 |
| 10 | 56 | F | 2nd | Left | Ipsilateral | Tenderness | 1 | 45 | 12 | Partially reduced | 8 |
| 11 | 81 | F | 1st | Right | Ipsilateral | Tenderness | 10 | 38 | 10 | Partially reduced | 6 |
| 12 | 34 | M | 1st | Left | Ipsilateral | None | 2 | 3 | 4 | Fully resolved | 3 |
| 13 | 58 | F | 1st | Left | Ipsilateral | None | 2 | 2 | 7 | Fully resolved | 1 |
*Corresponding to subjective palpable swelling by patients. †Reported by patients during telephone follow up. Covid-19 = coronavirus disease 2019; Pt no. = patient number; USS = ultrasound scan; F = female; M = male